black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Company profile
Ticker
BDTX
Exchange
Website
CEO
David M. Epstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aset Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Black Diamond Therapeutics Security Corporation ...
BDTX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Black Diamond Therapeutics Announces Changes to Board of Directors
11 Apr 24
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 Mar 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
4 Jan 24
8-K
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
13 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 58.80 mm | 58.80 mm | 58.80 mm | 58.80 mm | 58.80 mm | 58.80 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.00 mm | 7.29 mm | 6.12 mm | 6.23 mm |
Cash used (since last report) | n/a | n/a | 54.51 mm | 49.63 mm | 41.68 mm | 42.39 mm |
Cash remaining | n/a | n/a | 4.29 mm | 9.16 mm | 17.11 mm | 16.40 mm |
Runway (months of cash) | n/a | n/a | 0.5 | 1.3 | 2.8 | 2.6 |
Institutional ownership, Q3 2023
98.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 76 |
Opened positions | 17 |
Closed positions | 19 |
Increased positions | 23 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 100.20 bn |
Total shares | 51.13 mm |
Total puts | 37.90 k |
Total calls | 174.10 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLVGF Bellevue | 8.14 mm | $23.35 bn |
BBBOF BB Biotech | 5.38 mm | $0.00 |
NEA Management | 4.45 mm | $12.77 bn |
Versant Venture Capital VI | 4.33 mm | $14.42 mm |
Ra Capital Management | 3.53 mm | $10.12 bn |
New Enterprise Associates 16 | 3.45 mm | $131.05 mm |
T. Rowe Price Investment Management | 2.15 mm | $6.26 bn |
Artal | 2.05 mm | $5.87 mm |
Vanguard | 1.96 mm | $5.64 bn |
Verition Fund Management | 1.74 mm | $4.98 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | Shannon Campbell | Stock Option Common Stock | Grant | Acquire A | No | No | 4.98 | 61,100 | 304.28 k | 61,100 |
10 Apr 24 | Prakash Raman | Stock Option Common Stock | Grant | Acquire A | No | No | 4.98 | 61,100 | 304.28 k | 61,100 |
15 Mar 24 | Dixon Wendy L | Common Stock | Grant | Acquire A | No | No | 4.54 | 3,253 | 14.77 k | 38,054 |
News
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $16
8 Apr 24
Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
8 Apr 24
Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $10 Price Target
13 Mar 24
Black Diamond Therapeutic: Q4 Earnings Insights
12 Mar 24
Black Diamond Therapeutic Q4 EPS $(0.34) Beats $(0.47) Estimate; Cash, Cash Equivalents, And Investments Of $131.4M Expected To Be Sufficient To Fund Operations Into Q2 Of 2025
12 Mar 24
Press releases
Garry Menzel joins GHO Capital as Operating Partner
23 Apr 24
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
7 Apr 24
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
3 Apr 24